Oxidative and antioxidative status after anthracycline-based chemotherapy in breast cancer patients

被引:1
|
作者
Alacacioglu, A. [1 ]
Kebapcilar, L. [2 ]
Pamuk, B. Onder [2 ]
Sop, G. [2 ]
Kucukiravul, C. [2 ]
Bozkaya, G. [3 ]
Yuksel, A. [2 ]
Alacacioglu, I. [4 ]
Sari, I. [2 ]
机构
[1] Bozyaka Res & Training Hosp, Dept Med Oncol, TR-35360 Izmir, Turkey
[2] Bozyaka Res & Training Hosp, Dept Internal Med, TR-35360 Izmir, Turkey
[3] Bozyaka Res & Training Hosp, Dept Biochem, TR-35360 Izmir, Turkey
[4] Ataturk Training & Res Hosp, Dept Hematol, Izmir, Turkey
来源
JOURNAL OF BUON | 2013年 / 18卷 / 03期
关键词
anthracycline; breast cancer; SOD; TBARS;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The present study was undertaken to evaluate the effects of adjuvant anthracycline-based chemotherapy on thiobarbituric acid reactive substances (TBARS) and superoxide dismutase (SOD) levels in patients with breast cancer who had undergone surgery. Methods: Body mass index (BMI), serum lipids (total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides), serum TBARS and SOD values were assessed in 30 patients with stage III breast cancer receiving adjuvant anthracydine-based chemotherapy. Results: Anthracycline-based chemotherapy had no effect on BMI, blood pressure and lipid profile. A significant elevation was noted in TBARS (5.5 +/- 0.6 vs 5.9 +/- 0.9}anon; p=0.038) and a significant reduction to baseline values in SOD levels (226.5 +/- 61.0 vs 203.1 +/- 48.3 U/mL; p=0.037) in patients following 6 cycles of adjuvant chemotherapy. Conclusion: The TBARS levels increased, whereas the SOD levels descreased after anthracycline-based chemotherapy. We suggest that oxidative stress is not always detrimental, as it can be beneficial in cancer treatment.
引用
收藏
页码:614 / 618
页数:5
相关论文
共 50 条
  • [31] Adjuvant anthracycline-based chemotherapy for early breast cancer: do the dose and schedule matter?
    Mano, MS
    Awada, A
    Kerr, J
    Canney, P
    CANCER TREATMENT REVIEWS, 2005, 31 (02) : 69 - 78
  • [32] FKBP12 is a predictive biomarker for efficacy of anthracycline-based chemotherapy in breast cancer
    Mingyou Xing
    Jun Wang
    Qin Yang
    Yu Wang
    Jiansha Li
    Jing Xiong
    Sheng Zhou
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 861 - 872
  • [33] Dose and dose intensity effect of adjuvant anthracycline-based chemotherapy in early breast cancer -: A retrospective analysis
    Amador, ML
    Jimeno, A
    Hitt, R
    Cortés-Funes, H
    Colomer, R
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2004, 27 (03): : 269 - 273
  • [34] Association between the genetic polymorphisms of the pharmacokinetics of anthracycline drug and myelosuppression in a patient with breast cancer with anthracycline-based chemotherapy
    Cui, Lulu
    Huang, Jia
    Zhan, Yongtao
    Qiu, Ni
    Jin, Huan
    Li, Jia
    Huang, Huiqi
    Li, Hongsheng
    LIFE SCIENCES, 2021, 276
  • [35] The topoisomerase II alpha gene status in primary breast cancer is a predictive marker of the response to anthracycline-based neoadjuvant chemotherapy
    Kawachi, Kae
    Sasaki, Takeshi
    Murakami, Ayumi
    Ishikawa, Takashi
    Kito, Ayako
    Ota, Ikuko
    Shimizu, Daisuke
    Nozawa, Akinori
    Nagashima, Yoji
    Machinami, Rikuo
    Aoki, Ichiro
    PATHOLOGY RESEARCH AND PRACTICE, 2010, 206 (03) : 156 - 162
  • [36] Prediction of trastuzumab-induced cardiotoxicity in breast cancer patients receiving anthracycline-based chemotherapy: methodological issues
    Naderi, Mehdi
    Sabour, Siamak
    JOURNAL OF ECHOCARDIOGRAPHY, 2019, 17 (02) : 112 - 113
  • [37] Prediction of trastuzumab-induced cardiotoxicity in breast cancer patients receiving anthracycline-based chemotherapy: methodological issues
    Mehdi Naderi
    Siamak Sabour
    Journal of Echocardiography, 2019, 17 : 112 - 113
  • [38] Renal tubular dysfunction and urinary zinc excretion in breast cancer patients treated with anthracycline-based combination chemotherapy
    Králicková, P
    Melichar, B
    Malír, F
    Roubal, T
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2004, 23 (04): : 579 - 584
  • [39] Prognostic implication of HSPA (HSP70) in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy
    Silvina B. Nadin
    Mayra L. Sottile
    Maria M. Montt-Guevara
    Gisel V. Gauna
    Pedro Daguerre
    Marcela Leuzzi
    Francisco E. Gago
    Jorge Ibarra
    F. Darío Cuello-Carrión
    Daniel R. Ciocca
    Laura M. Vargas-Roig
    Cell Stress and Chaperones, 2014, 19 : 493 - 505
  • [40] Prognostic implication of HSPA (HSP70) in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy
    Nadin, Silvina B.
    Sottile, Mayra L.
    Montt-Guevara, Maria M.
    Gauna, Gisel V.
    Daguerre, Pedro
    Leuzzi, Marcela
    Gago, Francisco E.
    Ibarra, Jorge
    Dario Cuello-Carrion, F.
    Ciocca, Daniel R.
    Vargas-Roig, Laura M.
    CELL STRESS & CHAPERONES, 2014, 19 (04) : 493 - 505